Literature DB >> 25470047

Cancer: Resistance through repopulation.

Ian F Tannock1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25470047     DOI： 10.1038/nature14075

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

Review 1.  Adhesion-dependent multicellular drug resistance.

Authors:  S K Green; A Frankel; R S Kerbel
Journal:  Anticancer Drug Des       Date:  1999-04

Review 2.  Repopulation of cancer cells during therapy: an important cause of treatment failure.

Authors:  John J Kim; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

3.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; Y Y Wang; M R Pfeffer; J W Crawford; E Frei
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

4.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.

Authors:  Antonina V Kurtova; Jing Xiao; Qianxing Mo; Senthil Pazhanisamy; Ross Krasnow; Seth P Lerner; Fengju Chen; Terrence T Roh; Erica Lay; Philip Levy Ho; Keith Syson Chan
Journal:  Nature       Date:  2014-12-03       Impact factor: 49.962

5.  Impact of schedule duration on head and neck radiotherapy: accelerated tumor repopulation versus compensatory mucosal proliferation.

Authors:  John D Fenwick; Juan Pardo-Montero; Alan E Nahum; Zafar I Malik
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

Review 6.  The role of inflammation in bladder cancer.

Authors:  Georgios Gakis
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 7.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

Review 8.  Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.

Authors:  Jian Chen; Peng Shen; Xiao-chen Zhang; Meng-dan Zhao; Xing-guo Zhang; Liu Yang
Journal:  Clin Ther       Date:  2014-07-10       Impact factor: 3.393
  8 in total
  12 in total

Review 1.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

2.  CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.

Authors:  Minlan Yang; Yanru Li; Yang Ruan; Yan Lu; Dongjing Lin; Yinping Xie; Bing Dong; Qihua Dang; Chengshi Quan
Journal:  Mol Cell Biochem       Date:  2017-11-20       Impact factor: 3.396

Review 3.  A view on drug resistance in cancer.

Authors:  José Baselga; David M Hyman; Neil Vasan
Journal:  Nature       Date:  2019-11-13       Impact factor: 49.962

4.  Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.

Authors:  Chengjuan Zhang; Bing Wei; Peng Li; Ke Yang; Zhizhong Wang; Jie Ma; Yongjun Guo
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

5.  BP‑1‑102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways.

Authors:  Xiaoxia Jiang; Jian Tang; Mengjie Wu; Shitu Chen; Zhenzhen Xu; Haiyong Wang; Haohao Wang; Xiongfei Yu; Zhongqi Li; Lisong Teng
Journal:  Mol Med Rep       Date:  2019-01-24       Impact factor: 2.952

6.  Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.

Authors:  Margaretha A Skowron; Günter Niegisch; Gerhard Fritz; Tanja Arent; Joep G H van Roermund; Andrea Romano; Peter Albers; Wolfgang A Schulz; Michèle J Hoffmann
Journal:  J Exp Clin Cancer Res       Date:  2015-11-25

7.  Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.

Authors:  Ying Huang; Xiang Yang; Tianrui Xu; Qinghong Kong; Yaping Zhang; Yuehai Shen; Yunlin Wei; Guanlin Wang; Kwen-Jen Chang
Journal:  Int J Oncol       Date:  2016-05-16       Impact factor: 5.650

8.  Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.

Authors:  Madeleine Benguigui; Dror Alishekevitz; Michael Timaner; Dvir Shechter; Ziv Raviv; Sebastien Benzekry; Yuval Shaked
Journal:  Oncotarget       Date:  2017-12-20

9.  Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

Authors:  Licun Wu; Walter Blum; Chang-Qi Zhu; Zhihong Yun; Laszlo Pecze; Mikihiro Kohno; Mei-Lin Chan; Yidan Zhao; Emanuela Felley-Bosco; Beat Schwaller; Marc de Perrot
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

10.  Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells.

Authors:  Chen-Cheng Xue; Meng-Huan Li; Yang Zhao; Jun Zhou; Yan Hu; Kai-Yong Cai; Yanli Zhao; Shu-Hong Yu; Zhong Luo
Journal:  Sci Adv       Date:  2020-04-29       Impact factor: 14.957
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.